Organon Llc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$73.6M
Doctors Paid
49,910
Transactions
155,664
2024 Total
$13.4M
Payment Breakdown by Category
Research$54.2M (73.6%)
Food & Beverage$2.5M (3.4%)
Consulting$1.1M (1.5%)
Travel$388,017 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $54.2M | 7,651 | 73.6% |
| Compensation for serving as faculty or as a speaker for a medical education program | $11.5M | 14,510 | 15.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.4M | 1,789 | 4.6% |
| Food and Beverage | $2.5M | 129,411 | 3.4% |
| Consulting Fee | $1.1M | 127 | 1.5% |
| Travel and Lodging | $388,017 | 1,678 | 0.5% |
| Honoraria | $307,300 | 202 | 0.4% |
| Long term medical supply or device loan | $199,002 | 282 | 0.3% |
| Grant | $3,900 | 3 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $2,750 | 1 | 0.0% |
| Gift | $1,568 | 10 | 0.0% |
Payments by Type
Research
$54.2M
7,651 transactions
General
$19.4M
148,013 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| OG-8175A-023 | $31.4M | 0 | 3,977 |
| A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) | $2.2M | 0 | 466 |
| Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive: a Multicenter Trial | $1.9M | 2 | 31 |
| Efficacy and Safety of Nexplanon 36 to 60 Months Post Insertion | $1.8M | 0 | 434 |
| 8415-8415-060-PN060-Extended Duration Study (Celanese + 2 years)-Contraception-SC-imp-Supplemental Registration-USA-LD-B | $1.7M | 0 | 87 |
| OG-6219-P001 | $1.4M | 0 | 238 |
| A Phase 3, Open-label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of the Etonogestrel MK-8415 Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger | $1.4M | 0 | 1,685 |
| 8415-060 | $1.3M | 0 | 418 |
| Planning Healthy Pregnancies to Reduce Infant and Maternal Mortality | $1.2M | 0 | 17 |
| Implementation and Examination of Contraception Care for Hospitalized Adolescents with Mental Health Disorders | $846,046 | 0 | 11 |
| Assessing adolescent use of Nexplanon over time: a prospective, longitudinal study | $759,972 | 0 | 4 |
| Efficacy and Safety of Nexplanon 36 to 60 Months Post Insertion | $541,720 | 0 | 140 |
| Fostering LARC uptake among vulnerable adolescents: Understanding the barriers to LARC procedures in the inpatient hospital setting | $468,924 | 0 | 10 |
| A prospective observational study of preference for and efficacy of oral levonorgestrel emergency contraception with same day etonogestrel contraceptive implant compared to established pregnancy rates with oral levonorgestrel emergency contraception alone | $466,180 | 0 | 9 |
| Developing and testing an implementation toolkit to make long acting reversible contraceptives (LARCs) a reality in pediatric practices | $452,027 | 0 | 2 |
| Practice Transformation: Improving Nexplanon Provision in Adolescents | $451,945 | 0 | 6 |
| Nexplanon Training Barriers and Perspectives Among Family Medicine Residents in New Jersey | $422,278 | 0 | 8 |
| Effect of IL-4R?R576 polymorphism on response to dupilumab in asthma, a genotype-stratified, randomized, placebo- controlled trial | $414,436 | 0 | 6 |
| A pilot prospective, randomized pharmacodynamic study with assessment of ulipristal acetate on ovarian activity following quickstart of the etonogestrel contraceptive implant | $391,796 | 0 | 6 |
| Pharmacokinetic and pharmacodynamic evaluation of etonogestrel dose escalation with efavirenz-based antiretroviral therapy in HIV-infected Ugandan women | $369,503 | 0 | 7 |
| Treatment of unfavorable bleeding patterns in contraceptive implant users: a randomized clinical trial of curcumin | $340,530 | 0 | 8 |
| Reduction of premature discontinuation of contraceptive implants by advance provision of an OCP-based participant intervention: randomized clinical trial | $298,608 | 0 | 2 |
| Keep CALM (Contraceptive Arm Long-acting iMplant) and Carry on | $296,994 | 0 | 4 |
| Same-day insertion of long-acting reversible contraception in a single health system | $289,525 | 0 | 2 |
| Evaluating the Mobile Clinic Model as a Means of Increasing Access to Reproductive and Sexual Health | $263,531 | 1 | 2 |
| A 3-year Retrospective Review of Contraceptive Uptake, Continuation, Switching, and Pregnancy Among Adolescent Females In An Urban Teen Family Planning Clinic | $229,397 | 0 | 4 |
| A quasi-experimental, interrupted time series study to evaluate the effectiveness of "SexHealth Mobile" on uptake of contraception in women with substance use disorder | $207,718 | 0 | 4 |
| Intervention to Facilitate Contraception Provision by Pediatric Hospitalists: A Feasibility Study | $206,710 | 0 | 3 |
| Multi-level Intervention to Reduce Pregnancy Risk Among Adolescents: A Feasibility Trial in the Emergency Department | $197,449 | 0 | 24 |
| Barriers and Facilitators to Long-Acting Reversible Contraception: Perspectives of Adolescents and Young Adults and Healthcare Providers in Rural Haiti | $195,382 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors — Page 4
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Matthew Retzloff, M.d, M.D | Obstetrics & Gynecology | San Antonio, TX | $46,634 | $0 |
| Dr. Judith Burgis, M.d, M.D | Obstetrics & Gynecology | Columbia, SC | $46,253 | $0 |
| Dr. Michiel Noe, M.d, M.D | Specialist | El Paso, TX | $42,802 | $0 |
| Mrs. Ashleigh Butts-Wilkerson, M.d, M.D | Student in an Organized Health Care Education/Training Program | Mobile, AL | $42,447 | $0 |
| Catherine Mccarthy, Md, MD | Family Medicine | Reno, NV | $41,833 | $0 |
| Dr. Karen Mann, M.d, M.D | Obstetrics & Gynecology | Los Angeles, CA | $41,803 | $0 |
| Emmary Butler, Md, MD | Obstetrics & Gynecology | Wilkes Barre, PA | $41,535 | $0 |
| Audrey Roberts, Md, MD | Obstetrics & Gynecology | Flagstaff, AZ | $41,500 | $0 |
| Andrea Roe, Md, MD | Obstetrics & Gynecology | Philadelphia, PA | $41,226 | $0 |
| Dr. Amanda Carroll, D.o, D.O | Obstetrics & Gynecology | Festus, MO | $41,201 | $0 |
| Anna Celaya, M.d, M.D | Obstetrics & Gynecology | Torrance, CA | $40,888 | $0 |
| Dr. Brian Harvey, Md, MD | Internal Medicine | Annapolis, MD | $40,300 | $0 |
| Sarah Eiser, M.d, M.D | Obstetrics & Gynecology | Lancaster, PA | $40,096 | $0 |
| Amna Dermish, Md, MD | Obstetrics & Gynecology | Austin, TX | $39,112 | $0 |
| Dr. Dipak Delvadia, D.o, D.O | Obstetrics & Gynecology | Cherry Hill, NJ | $39,067 | $0 |
| Jennifer Grigg, Aprn, APRN | Nurse Practitioner | Columbia, MO | $38,613 | $0 |
| Timothy Bell, D.o, D.O | Obstetrics & Gynecology | Fort Smith, AR | $38,586 | $0 |
| Hilary Miller | Women's Health | Oklahoma City, OK | $37,825 | $0 |
| Patti Ross, M.d, M.D | Obstetrics & Gynecology | Houston, TX | $37,734 | $0 |
| Dr. Denise Bayuszik, M.d, M.D | Obstetrics & Gynecology | Spokane, WA | $37,454 | $0 |
| Dr. Kimberly Looney, Md, MD | Obstetrics & Gynecology | Nashville, TN | $37,161 | $0 |
| Virginia Clementson, Aprn-Cnp, APRN-CNP | Women's Health | Mankato, MN | $36,216 | $0 |
| Rachel Guy, Np, NP | Family | Middlebury, VT | $35,964 | $0 |
| Dr. Sarah Hall, D.o, D.O | Family Medicine | Tulsa, OK | $35,934 | $0 |
| Anita Nelson, M.d, M.D | Obstetrics & Gynecology | Torrance, CA | $35,670 | $0 |
Ad
Top Products
- NEXPLANON $17.2M
- IMPLANON $3.1M
Associated Products (8)
- NEXPLANON $28.9M
- Nexplanon $2.4M
- HADLIMA $176,656
- ONTRUZANT $50,573
- REMERONSOLTAB $45,288
- GANIRELIX ACETATE $30,510
- PREGNYL $22,009
- Ganirelix Acetate $10,195
Payment Categories
- Food & Beverage $2.5M
- Consulting $1.1M
- Travel & Lodging $388,017
- Research $54.2M
About Organon Llc
Organon Llc has made $73.6M in payments to 49,910 healthcare providers, recorded across 155,664 transactions in the CMS Open Payments database. In 2024, the company paid $13.4M. The top product by payment volume is NEXPLANON ($17.2M).
Payments were distributed across 219 medical specialties. The top specialty by payment amount is Obstetrics & Gynecology ($7.3M to 12,544 doctors).
Payment categories include: Food & Beverage ($2.5M), Consulting ($1.1M), Research ($54.2M), Travel & Lodging ($388,017).
Organon Llc is associated with 8 products in the CMS Open Payments database, including NEXPLANON, Nexplanon, and HADLIMA.